Table 3.

Basic characteristics of FMT patients – supernatant (a) and sediment (b) group.

Oszlop1	Patient #1	Patient #2	Patient #3	Patient #4	Patient #5
Group	Supernatant	Supernatant	Supernatant	Supernatant	Supernatant
Age	83	82	66	62	62
Sex	Male	Female	Female	Female	Male
Number of recurrences	4	2	4	2	22
Previous antibiotics	metronidazole, vancomycin, fidaxomicin	metronidazole, vancomycin, fidaxomicin	metronidazole, vancomycin, fidaxomicin	metronidazole	metronidazole, vancomycin, fidaxomicin
Risk factors	rCDI	radiation colitis, small bowel resection, UTI - augmentin (amoxicillin + clavulanic acid), ceftriaxon, hospitalisation, rCDI	IBD, colectomy rCDI	rCDI	rCDI
Firs FMT successful?	Yes	Yes	Yes	Yes	No
b
Oszlop1	Patient #6	Patient #7	Patient #8	Patient #9	Patient #10
Group	Sediment	Sediment	Sediment	Sediment	Sediment
Age	82	43	76	66	77
Sex	Female	Male	Female	Male	Female
Number of recurrences	2	2	3	3	2
Previous antibiotics	metronidazole, vancomycin	metronidazole, vancomycin	metronidazole, vancomycin, fidaxomicin	vancomycin	metronidazole, vancomycin
Risk factors	UTI - ceftriaxon, rCDI	Antibiotic treatment against respiratory tract infection, rCDI	UTI - levofloxacin, pneumonia - imipenem, ceftriaxon, rCDI	augmentin (amoxicillin + clavulanic acid)	imipenem, cilastatin, augmentin (amoxicillin + clavulanic acid), rifampicin